• Advaxis Inc., of Princeton, N.J., reported final 18-month survival data from Lm-LLO-E7-15, a Phase II study evaluating safety and efficacy of ADXS-HPV (ADXS11-001) with and without cisplatin in 110 patients with recurrent cervical cancer in two treatment arms of 55 patients each, with survival at 28 percent (31/110), updated from the preliminary 18-month survival rate of 22 percent (16/73) reported at the American Society of Clinical Oncology meeting earlier this year.